|| List of recent Peptide-related patents
|System and predicting the immunogenicity of a peptide|
A system, computer readable storage medium and method of predicting the immunogenicity of a peptide are provided. In certain cases the system includes: a) a model of a peptide, a model of a mhcii protein and a model of a t cell receptor; and b) an executable program for: (i) evaluating the strength of intermolecular interactions of a complex containing the peptide, the mhcii protein and the t cell receptor to provide a score that predicts the immunogenicity of the peptide; and (ii) outputting the score..
Bayer Healthcare Llc
|Method for detecting at least one mechanism of resistance to glycopeptides by mass spectrometry|
The present invention relates to a method of detection, for at least one microorganism contained in a sample, of at least one marker of resistance to a glycopeptide, including the detection, by mass spectrometry, of at least one peptide or protein of said microorganism. Preferably, the glycopeptide is vancomycin.
|Peptides, devices, and methods for the detection of anaplasma antibodies|
The invention provides populations of isolated peptides useful for the detection of antibodies that bind to anaplasma antigens. The peptide populations comprise peptides derived from immunogenic fragments of the anaplasma outer membrane protein proteins.
|Materials for hydrophilic interaction chromatography and processes for preparation and use thereof for analysis of glycoproteins and glycopeptides|
The invention relates to poly-amide bonded hydrophilic interaction chromatography (hilic) stationary phases and novel hilic methods for use in the characterization of large biological molecules modified with polar groups, known to those skilled in the art as glycans. The invention particularly provides novel, poly-amide bonded materials designed for efficient separation of large biomolecules, e.g.
Waters Technologies Corporation
|Screening methods for transfusion related acute lung injury (trali)|
The invention relates to the discovery that hna-3a and hna-3b are antigens within a polypeptide sequence that is highly similar to the ctl2 amino acid sequence. This invention provides methods and kits for screening for hna-3a and hna-3b specific antibodies, hna-3a and hna-3b polypeptides and hna-3a and hna-3b nucleic acids in a sample of a biological tissue intended for transplantation.
Drk Blutspendedienst West Gmbh
|Polypeptides having oxidoreductase activity and their uses|
The invention relates to a polypeptide having oxidoreductase activity which comprises the amino acid sequence set out in seq id no: 3 or an amino acid sequence encoded by the nucleotide sequence of seq id no: 4, or a variant polypeptide thereof having 45% or more sequence identity with the sequence of seq id no: 3. The invention also relates to a process for the production of 2,5-furan-dicarboxylic acid (fdca) or production of 5-hydroxymethyl-2-furancarboxylic acid (hmf acid)..
Purac Biochem B.v.
|Methods and microorganisms for the biological synthesis of (s) -2-amino-6-hydroxypimelate, hexamethylenediamine and 6-aminocaproate|
A chemical having the formula (s) 2-amino-6-hydroxypimelate. (s)-2-amino-6-hydroxypimelate can be made using a method comprising culturing a cell comprising an exogenous nucleic acid sequence encoding an enzyme that catalyzes the substrate to product conversion of (s)-2-amino-6-oxopimelate to (s)-2-amino-6-hydroxypimelate and separating the (s)-2-amino-6-hydroxypimelate.
|Recombinant bacteria comprising novel sucrose transporters|
Recombinant bacteria capable of metabolizing sucrose are described. The recombinant bacteria comprise in their genome or on at least one recombinant construct, a novel nucleotide sequence encoding a polypeptide having sucrose transporter activity and a nucleotide sequence encoding a polypeptide having sucrose hydrolase activity.
E.i. Du Pont De Nemours And Company
|Increased isoprene production using the archaeal lower mevalonate pathway|
The invention features methods for producing isoprene from cultured cells using a feedback-resistant mevalonate kinase polypeptide, such as an archaeal mevalonate kinase polypeptide. The resulting isoprene compositions may have increased yields and/or purity of isoprene..
The Goodyear Tire & Rubber Company
|Transcription activator-like effector (tale) fusion protein|
The present invention relates to transcription activator-like effector (tale) derived proteins that allow to efficiently target and/or process double stranded nucleic acid sequences. The proteins of the invention are typically chimeric protein monomers composed of a core scaffold comprising repeat variable dipeptide regions (rvds) having binding specificity to a dna target sequence, to which is fused a catalytic domain to its n-terminal.
Genetic engineering method and material for increasing plant yield
A method includes increasing expa1 gene expression or increasing the activity of expa1 polypeptide to produce a plant with an improved trait. The method may further include increasing the expression of rdl1 gene or the activity of rdl1 kpolypeptide.
Shanghai Institutes For Biological Sciences, Cas
Increased protein expression in plants
This disclosure concerns synthetic polynucleotides encoding a polypeptide of interest that are particularly well-suited for expression in target plants.. .
Dow Agrosciences Llc
Aspergillus containing beta-glucosidase, beta-glucosidases and nucleic acids encoding the same
A novel microorganism is provided named aspergillus saccharolyticus. Further, beta-glucosidase enzymes encoded by said microorganism are provided, and the use thereof in the degradation of lignocellulosic material.
Polypeptides having cellulolytic enhancing activity and polynucleotides encoding same
Provided are isolated polypeptides having cellulolytic enhancing activity and polynucleotides encoding the polypeptides, catalytic domains or carbohydrate binding modules. Also provided are nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or carbohydrate binding modules..
Compositions comprising nucleic acids encoding hiv-1 reverse transcriptase ctl epitopes
The present invention provides peptides and proteins for use in second generation hiv vaccines and as diagnostic tools in the treatment and control of hiv infection. The antiviral protection shown by compositions of the present invention has not been previously achieved with an hla epitope-enhanced vaccine.
The Government Of The United States Of America As Represented By The Secretary Of The Departmen Of H
Modified tafazzin proteins and methods of making and using the same
Fusion proteins comprising a tafazzin peptide and a cellular permeability peptide are disclosed. The tafazzin peptide may be coupled to the permeability peptide through a polypeptide linker.
University Of Washington Center For Commercialization
Use of pre t alpha or functional variant thereof for expanding tcr alpha deficient t cells
A method of expanding tcralpha deficient t-cells by expressing ptalpha or functional variants thereof into said cells, thereby restoring a functional cd3 complex. This method is particularly useful to enhance the efficiency of immunotherapy using primary t-cells from donors.
Method for the production of permanent human cell lines
The present invention relates to a method for the production of a permanent human cell line, wherein isolated primary human cells are transfected simultaneously with a sequence allowing the expression of at least one cell transforming factor and a sequence allowing the expression of at least one recombinant polypeptide.. .
Cevec Pharmaceuticals Gmbh
Protein-containing adhesives, and manufacture and use thereof
The invention provides protein adhesives and methods of making and using such adhesives. The protein adhesives contain ground plant meal or an isolated polypeptide composition obtained from plant biomass..
Biopolymer Technologies, Ltd.
Polymers of isropene from renewable resources
It has been found that certain cells in culture can convert more than about 0.002 percent of the carbon available in the cell culture medium into isoprene. These cells have a heterologous nucleic acid that (i) encodes an isoprene synthase polypeptide and (ii) is operably linked to a promoter.
The Goodyear Tire & Rubber Company
Variants of igg fc with limited amine groups
Lysine-depleted variants of fragment crystallizable (fc) regions of immunoglobulins are disclosed. Also disclosed are fusion proteins comprised of n-terminal targeting or active peptide domains fused with such lysine-depleted variant igg-fc domains.
Fviii peptides for immune tolerance induction and immunodiagnostics
The present invention is related to peptides that can be used to reduce the immune response against fviii or to induce tolerance to human fviii in patients with, e.g., hemophilia a. Furthermore, the peptides can be used for immunodiagnostic purposes to detect fviii-specific cd4+t cells to monitor patients with hemophilia a during replacement therapy and during immune tolerance induction therapy..
Baxter Healthcare Sa
B7-h5, a costimulatory polypeptide
B7-h5 costimulatory polypeptides, nucleic acids encoding such polypeptides, and methods for using the polypeptides and nucleic acids to enhance a t cell response are provided herein.. .
Mayo Foundation For Medical Education And Research
Compounds and methods for modulating pharmacokinetics
Methods and compositions are described for management of the pharmacokinetic properties of active agents, e.g., therapeutic moieties, by conjugating, fusing, or non-direct linkage of the active agent to one or more wild-type or modified heparin-binding peptides (hb). Compounds may be administered to tissues including skin.
The Brigham And Women's Hospital, Inc.
Beta thymosin fragments
peptide fragments having amino acid sequences corresponding to portions of a thymosin beta 4, a thymosin beta 10 and/or a thymosin beta 15 amino acid sequence are provided, as well as methods of treatment utilizing same.. .
Regenerx Biopharmaceuticals, Inc.
Proproteins and methods of use thereof
The present disclosure provides for proprotein and activatable proprotein compositions. A proprotein contains a functional protein (i.e.
Cytomx Therapeutics, Inc.
Long-acting polypeptides and methods of producing same
A polypeptide and polynucleotides encoding same comprising one carboxy-terminal peptide (ctp) of chorionic gonadotrophin attached to an amino terminus of a cytokine and two carboxy-terminal peptides (ctp) of chorionic gonadotrophin attached to a carboxy terminus of a cytokine are disclosed. Pharmaceutical compositions comprising the polypeptide and polynucleotides of the invention and methods of using same are also disclosed..
Opko Biologics Ltd.
Alpha/beta-peptide mimics of z-domain peptides
Described are α/β-peptide mimics of z-domain scaffold peptides, methods of making them, and methods of using them. The α/β-peptide mimics include β-amino acid residues and, optionally, disulfide bonds to stabilize the conformation of the mimics.
Wisconsin Alumni Research Foundation
Ige peptide vaccine
It is intended to provide an ige peptide vaccine that can be used in the prevention or treatment of allergic diseases in animals other than mice, such as humans or dogs. The present invention provides a peptide consisting of (i) the amino acid sequence represented by seq id no: 28, or (ii) an amino acid sequence consisting of at least 10 consecutive amino acids in the amino acid sequence represented by seq id no: 28, wherein the peptide, when administered to an animal, is capable of specifically binding to a ch3 region in an ige antibody of the animal and thereby blocking the binding of the ige antibody to an ige receptor..
Nippon Zenyaku Kogyo Co., Ltd.
Scytodes venom fiber peptides, nucleic acids and methods of making and using
The present invention is directed to spider silk-like fibers, peptides comprising the fibers, nucleic acids encoding the peptides, nucleic acid constructs and recombinant expression vectors, fusion peptides and methods of making and using the foregoing.. .
Methods for treating psychiatric disorders or symptoms thereof using ncam peptide mimetics
The present invention provides methods for treating or alleviating one or more symptoms of depression and/or anxiety in a subject comprising administering an effective amount of an ncam peptide mimetic to the subject. The symptoms of depression and/or anxiety are typically observed in or associated with a neurological condition.
The Board Of Trustees Of The Leland Stanford Junior University
Immune system mediator
The present invention discloses an isolated nucleic acid molecule encoding an israa polypeptide comprising a nucleotide sequence exhibiting at least 70% homology to the sequence represented by the nucleotide sequence seq id no: 1. Also disclosed is a recombinant expression vector comprising said nucleic acid molecule and an isolated polypeptide molecule encoded by said nucleic acid molecule..
Arabian Gulf University
Flagellin related polypeptides and uses thereof
The use of flagellin and flagellin related polypeptides for the protection of mammals from the effects of apoptsis is described.. .
Cleveland Clinic Foundation
Modified compstatin with peptide backbone and c-terminal modifications
Compounds comprising peptides capable of binding c3 protein and inhibiting complement activation are disclosed. These compounds display greatly improved complement activation-inhibitory activity as compared with currently available compounds.
The Trustees Of The University Of Pennsylvania
Compositions and methods of using islet neogenesis peptides and analogs thereof
The invention provides peptides and analogs of ingap and hip peptides. The peptides and analogs can be used in methods for treating various diseases and conditions.
Shenzhen Hightide Biopharmaceutical, Ltd.
Inhibition of gliadin peptides
Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided.
Alba Therapeutics Corporation
The present invention provides peptides corresponding to fragments of cd31 that inhibit platelet and leukocyte activation, and to their use in the treatment of thrombotic disease. These peptides find use as therapeutic agents in the treatment of inflammatory diseases and thrombotic diseases such as atherothrombosis, in particular when immobilised onto solid supports..
Assistance Publique - Hopitaux De Paris
Method of recovering peptide and detecting peptide
Disclosed is a method of recovering a peptide, including: mixing a liquid sample containing a complex of peptide and protein in blood with a reagent containing a neutral amino acid, an acidic amino acid or both the neutral and acidic amino acids to liberate the peptide from the protein in blood; and recovering the liberated peptide.. .
New polyphosphate synthesis
The subject of the invention is a new method of the synthesis of polyphosphate analogues, such as nucleosides, oligonucleotides, carbohydrates, peptides and proteins, which are of biological importance and are used in organic chemistry, molecular biology and biotechnology. Polyphosphate analogues, including in particular nucleoside 5′-triphosphates, display high biological activity and are responsible for the provision and storage of energy in live organisms.
Instytut Chemii Bioorganicznej Polskiej Akademii Nauk
Dispersion and forming hydrogel
There is provided a dispersion containing a lipid peptide type compound useful as a low molecular weight gelator and a solvent capable of dissolving the lipid peptide type compound at a lower temperature. There is provided also a dispersion from which a hydrogel can be formed by a simpler method and from which a gel can be obtained as a gel having high thermal stability, and provide a method for forming the gel.
Nissan Chemical Industries, Ltd.
Matrix scaffold with antimicrobial activity
The invention provides a scaffold of extracellular matrix polymers with recombinant chimeric peptides tethered thereto. The invention also provides recombinant chimeric peptides of antimicrobial peptides and extracellular matrix binding domains.
Contrast agents, methods for preparing contrast agents, and methods of imaging
Provided is a protein contrast agent for enhancing an mri image and comprising a polypeptide having a conformation presenting at least five oxygen atoms positioned to chelate at least one paramagnetic metal ion such as gd3+, each oxygen atom being between about 2 angstrom units and about 5 angstrom units from the metal ion; the metal ion has at least one water molecule electrostatically interacting a distance of less than about 10 angstrom units a target-specific moiety conjugated thereto, at least one polyethylene glycol molecule, and a paramagnetic metal ion. Also provided is a method of obtaining an enhanced mri image using the protein contrast agent to a t2/t1 or t1/t2 intensity ratio of the mri image; and (d) obtaining an image of the t2/t1 or t1/t2 intensity ratio..
Georgia State University Research Foundation, Inc.
Intestinal peptide targeting ligands
peptide ligands for transporting therapeutic agents across the intestinal epithelial barrier that ordinarily are inadequately absorbed and must be delivered by alternative means, which contain an isolated amino acid sequence wherein at least one pair of amino acids are of an opposite charge and the pair members are separated by a spacer of 1-12 amino acid residues including at least one hydrophobic amino acid, and wherein the length of the amino acid sequence is greater than 5 and less than 20 amino acids. Pharmaceutical compositions for gastro-intestinal delivery and methods for the gastrointestinal delivery of poorly absorbed therapeutic agents are also disclosed..
Rutgers, The State University Of New Jersey
Aberrant cell-restricted immunoglobulins provided with a toxic moiety
Described are immunoglobulins provided with a toxic moiety, comprising at least an immunoglobulin variable region that specifically binds to an mhc-peptide complex preferentially associated with aberrant cells. These immunoglobulins provided with a toxic moiety are preferably used in selectively modulating biological processes.
Dipeptide-based prodrug linkers for aliphatic amine-containing drugs
The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof, comprising a drug linker conjugate d-l, wherein d being a biologically active moiety containing an aliphatic amine group is conjugated to one or more polymeric carriers via dipeptide-containing linkers l. Such carrier-linked prodrugs achieve drug releases with therapeutically useful half-lives.
Ascendis Pharma A/s
Lung cancer specific peptides for targeted drug delivery and molecular imaging
A conjugate is disclosed. The conjugate comprises (a) an isolated or a synthetic targeting peptide of less than 15 amino acid residues in length, comprising an amino acid sequence having at least 90% identity to a sequence selected from the group consisting of seq id nos: 1-8; and (b) a component conjugated to the targeting peptide, the component being selected from the group consisting of a drug delivery vehicle, an anti-cancer drug, a micelle, a nanoparticle, a liposome, a polymer, a lipid, an oligonucleotide, a peptide, a polypeptide, a protein, a cell, an imaging agent, and a labeling agent.
Cancer targeting peptides for enhancing anti-cancer drug delivery and therapeutic efficencies
A peptide targeted conjugate is disclosed. The conjugate comprises: (a) an isolated or a synthetic targeting peptide of less than 15 amino acid residues in length, comprising an amino acid sequence having at least 90% identity to a sequence selected from the group consisting of seq id nos: 1, 2 and 3; and (b) a component, to which the targeting peptide is conjugated, the component being selected from the group consisting of a drug delivery vehicle, an anti-cancer drug, a micelle, a nanoparticle, liposomes, a polymer, a lipid, an oligonucleotide, a peptide, a polypeptide, a protein, a cell, an imaging agent, and a labeling agent.
Interferon-alpha fusion protein in which cytoplasmic transduction peptide and polyethylene glycol are bonded to one another
The present invention relates to ifn-α fusion protein in which a cytoplasmic transduction peptide (ctp) and polyethylene glycol (peg) are bonded to an ifn-α protein. The ifn-α fusion protein of the present invention is characterized in that the specific activity of interferon remains high, the half-life of the inf-α fusion protein is extended when delivered in vivo, and the mobility of the interferon in a liver is improved.
Jw Creagene Inc.
[means for solving the problem] a water-insoluble complex comprising a water-soluble collagen peptide complexed with theaflavins and/or epicatechin.. .
Method for administering glp-1 molecules
The invention relates to formulations that demonstrate the feasibility of oral absorption comprising glucose-like peptide-1 compounds and specified delivery agents, and to methods of stimulating glp-1 receptor in a subject in need of such stimulation, by administration of the formulation of the present invention.. .
Emisphere Technologies, Inc.
The application relates to a yersinia pseudotuberculosis cell, which comprises nucleic acid coding for expression of at least one yersinia pestis caf1 polypeptide or of at least one antigenic fragment of yersinia pestis caf1, more particularly to an attenuated y. Pseudotuberculosis cell, which expresses the y.
Prostate-specific tumor antigens and uses thereof
Twenty-one psgr-derived peptides predicted by an immuno-informatics approach based on the hla-a2 binding motif were examined for their ability to induce peptide-specific t cell responses in peripheral blood mononuclear cells (pbmcs) obtained from either hla-a2+ healthy donors or hla-a2+ prostate cancer patients. The recognition of hla-a2 positive and psgr expressing lncap cells was also tested.
Dna vaccine containing vegf-specific epitope and/or angiopoietin-2-specific epitope
The present invention provides a therapeutic or prophylactic agent for cancer, containing an expression vector encoding a chimeric hepatitis b virus core antigen polypeptide inserted with an amino acid sequence containing a specific epitope of vegf and/or a specific epitope of angiopoietin-2, wherein the amino acid sequence containing the specific epitope is inserted between the amino acid residues 80 and 81 of the hepatitis b virus core antigen polypeptide.. .
Anges Mg, Inc.
Recombinant human albumin-human granulocyte colony stimulating factor for the prevention of neutropenia
Disclosed are compositions and methods for treating, preventing and ameliorating conditions and diseases characterized by a lowered white blood cell count. The methods and compositions described herein include a fusion polypeptide formed from human serum albumin protein (“hsa”) and human granulocyte-colony stimulating factor (“g-csf”)..
Teva Pharmaceutical Industries Ltd.
Neurturin polypeptides which possess reduced heparin and heparan sulfate binding affinity but retain neurotrophic activity, nucleic acids which encode the neurturin variants and vectors and host cells which express the enhanced neurturin polypeptides. Use of the enhanced neurturin polypeptides, nucleic acids and host cells in the treatment or prevention of disease..
Ntf Therapeutics, Inc.
Endoglin peptides to treat fibrotic diseases
In certain aspects, the present disclosure relates to the insight that a polypeptide comprising a truncated, ligand-binding portion of the extracellular domain of endoglin (eng) polypeptide may be used to treat fibrotic disorders.. .
Acceleron Pharma, Inc.
Multimeric tie 2 agonists and uses thereof in stimulating angiogenesis
The present invention provides a multimeric form of a tie 2 binding peptide monomer, wherein the multimeric form has tie 2 agonist activity. The multimeric form, preferably a tetramer, stimulates angiogenesis and promotes wound healing.
Sunnybrook Health Sciences Centre
Use of fusion protein comprising at least one polypeptide b, comprising type 1 ribosome inactivating protein, and at least one c having anticancer properties in the manufacture of a medicament for treating cancer in a subject in need thereof.. .
Biovalence Sdn. Bhd.
Anti-androgen peptides and uses thereof in cancer therapy
The present invention relates to isolated or purified or partially purified peptide derived molecules having the following general formula (s1): x-[(pro)n-his-pro-his-ala-arg-ile-lys]m-y. The peptides are for medical use, in particular as anti-tumoral agents..
Cancer Research Technology Limited
Anticonvulsant combination therapy
The present invention is directed to a pharmaceutical composition comprising a compound (a) of a class of peptide compounds and at least one further compound (b) for the prevention, alleviation or/and treatment of epileptic seizures.. .
Ucb Pharma Gmbh
Lipid membrane structure having intranuclear migrating property
A lipid membrane structure for delivering a substance into a nucleus of a cell, wherein lipid membrane is modified with (a) a polypeptide comprising the amino acid sequence of seq id no: 1, and/or (b) a polypeptide consisting of an amino acid sequence comprising the amino acid sequence of seq id no: 1, but including deletion and/or substitution and/or insertion of one or several amino acid residues, and having an activity of promoting migration of the lipid membrane structure into a nucleus of a cell, which can efficiently deliver a nucleic acid into a nucleus of an immunocyte such as dendritic cell.. .
National University Corporation Hokkaido University
Provided is a composition in which the dispersibility of a specific modified peptide is less likely to decrease at a ph of less than 7.0. The cosmetic composition contains a modified peptide having one or more side chain groups including one or more units selected from the group consisting of a structure represented by formula (ia): —s—s—(ch2)n—cooh, wherein n is 1 or 2, a structure represented by formula (ib): —s—s—ch(ch3)—cooh, a structure represented by formula (ic): —s—s—ch(cooh)—ch2—cooh, and salts of these structures; and a long-chain alkyltrimethylammonium salt or an n-long-chain alkylpyridinium salt, wherein the ratio of the total content of the long-chain alkyltrimethylammonium salt and the n-long-chain alkylpyridinium salt to the content of the modified peptide is 0.5 or more, and the cosmetic composition has a ph of less than 7.0..
Milbon Co., Ltd.
The present invention relates to a protein hydrolysate, wherein the hydrolysate has a percentage of peptides having a histidine residue at the c-terminal end of at least 10 wt % of the total peptide content of the protein hydrolysate and a process for preparing the protein hydrolysate. The invention further relates to a food or feed product comprising the protein hydrolysate..
Dsm Ip Assets B.v.
Method for detecting cancer
This invention provides: a method for detecting a cancer, comprising measuring the expression of a polypeptide having binding reactivity through antigen-antibody reaction with an antibody against caprin-1 having an amino acid sequence shown in any even-numbered seq id no shown in seq id nos: 2 to 30 in the sequence listing in a biological sample; a method for detecting a cancer which involves determining the presence and the amount of caprin-1 in a sample of a cancer patient in order to determine the administration of a therapeutic drug targeting caprin-1 to the cancer patient; and a drug and a kit for the diagnosis of a cancer, comprising an anti-caprin-1 antibody.. .
Toray Industries, Inc.
Functionalized nanopipette biosensor
Disclosed are methods and devices for biomolecular detection, comprising a nanopipette, exemplified as a hollow inert, non-biological structure with a conical tip opening of nanoscale dimensions, suitable for holding an electrolyte solution which may contain an analyte such as a protein biomolecule to be detected as it is passed through the tip opening. Biomolecules are detected by specific reaction with peptide ligands chemically immobilized in the vicinity of the tip.
The Regents Of The University Of California